


Claims:

1. Form B of seletalisib, represented by formula (IA):



(IA)

wherein n is at least 0.9 and no more than 2.1, having an XRPD pattern that exhibits characteristic peaks at 11.0° to 11.1° , 12.5° to 12.6° , 20.9° to 21.1° , and 22.9° to 23.0° $2\theta \pm 0.2^\circ$ 2θ using Cu $K\alpha$ radiation.

2. Form B of seletalisib as claimed in claim 1, wherein n is 1.0.

3. Form B of seletalisib as claimed in claim 1, wherein n is 2.0.

4. Form B of seletalisib as claimed in any one of the preceding claims, that exhibits an endothermic event at $146^\circ\text{C} \pm 6^\circ\text{C}$ in the DSC thermogram.

5. Form F of seletalisib, wherein Form F is an anhydrous crystal form thereof, having an XRPD pattern that exhibits characteristic peaks at 6.4° , 8.7° , 15.2° , 15.5° , and 20.3° $2\theta \pm 0.2^\circ$ 2θ using Cu $K\alpha$ radiation.

6. Form F of seletalisib as claimed in claim 5, that exhibits a melting endotherm at $238.5^\circ\text{C} \pm 5^\circ\text{C}$ in the DSC thermogram.

7. A pharmaceutical composition comprising Form B or Form F of seletalisib as defined in any one of claims 1 to 6 in association with a pharmaceutically acceptable carrier.

5 8. Form B or Form F of seletalisib as defined in any one of claims 1 to 6 for use in therapy.

9. Form B or Form F of seletalisib as defined in any one of claims 1 to 6 for use in the treatment and/or prevention of an adverse inflammatory, autoimmune,
10 cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic condition.

10. The use of Form B or Form F of seletalisib as defined in any one of claims 1 to 6 for the manufacture of a medicament for the treatment and/or prevention of an
15 adverse inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic condition.